title: Sodium oxybate and sleep apnea: a clinical case.
abstract: Sodium oxybate (GHB, Xyrem, Jazz Pharmaceuticals) is used to treat cataplexy in patients with narcolepsy. We report the case of a middle aged, normo-ponderal narcoleptic woman without risk factors who developed reversible sleep apnea and objective sleepiness when treated by sodium oxybate, with an apnea-hypopnea index (AHI) of 19.7 on sodium oxybate and AHI 4.8 without treatment. Despite a subjective improvement in vigilance, mean sleep latency on MWT decreased from 21 minutes to 8 minutes on sodium oxybate.
authors.affiliation: AP-HP Hôpital Raymond Poincaré, Sleep Unit, Physiology Department, Versailles-St Quentin en Yvelines University, France. sarah.hartley@rpc.aphp.fr
authors.forename: Sarah
authors.initials: S
authors.lastname: Hartley
authors.forename: Maria-Antonia
authors.initials: MA
authors.lastname: Quera-Salva
authors.forename: Mourad
authors.initials: M
authors.lastname: Machou
mesh_terms: D000328:Adult; D002385:Cataplexy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002492:Central Nervous System Depressants / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009290:Narcolepsy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D020189:Nocturnal Myoclonus Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017286:Polysomnography / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index; D012891:Sleep Apnea Syndromes / Q000139:chemically induced* / Q000175:diagnosis; D012978:Sodium Oxybate / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002492:Central Nervous System Depressants; D012978:Sodium Oxybate